Novo Nordisk A/S (NVO) plans to significantly reduce the official U.S. list prices for its two key drugs, Wegovy and Ozempic, starting next year, aiming to capture a larger share of the obesity treatment market. The Danish pharmaceutical company will set a uniform monthly price of $675 for its entire semaglutide-based drug series, representing a reduction of up to 50%. Its U.S. competitor Eli Lilly's (LLY) comparable weight-loss drug, Zepbound, currently has an official list price of $1,086.37 per month. This price cut targets the wholesale acquisition cost, and this public list price does not reflect the complex rebate system in the U.S. market. For those with commercial insurance, the out-of-pocket cost for patients using Zepbound and Wegovy can be as low as $25 per month. Novo Nordisk's head of U.S. operations, Jamey Millar, stated that this price reduction does not apply to the current cash-pay price in the U.S. but could ease the out-of-pocket burden for some insured patients, particularly those enrolled in plans where they pay a percentage of the drug's cost. "I believe payers will accept and welcome this price reduction, as they have publicly called for lower drug prices," Millar said, adding that, in isolation, this move will not impact the company's net sales. Currently, Novo Nordisk is implementing multiple pricing strategies to enhance its competitiveness in the obesity sector. Millar, a U.S. pricing strategy expert who previously worked at Optum Rx, the pharmacy benefit manager under UnitedHealth Group (UNH), noted that the new prices will take effect on January 1 next year. Millar indicated that the company needed to announce the price cut now to give payers time to adjust for the upcoming year. He pointed out that this adjustment will be particularly impactful for individuals with high-deductible health plans, where out-of-pocket costs are closely tied to the official list price. Patients with co-insurance plans, where they pay a percentage of the drug's cost, will also benefit. According to KFF's Employer Health Benefits Survey, last year about one-third of enrolled workers were in high-deductible plans paired with a health savings account. The same survey showed that less than half of large firms provided health insurance coverage for GLP-1 weight-loss drugs like Wegovy. This official price reduction will be implemented concurrently with, but independently from, the discounts negotiated last year by the U.S. government for Medicare patients. Millar emphasized that the two price reductions are separate and unrelated.